However, CAR-T therapy can overcome the immunosuppressive nature of the tumor microenvironment and achieve precise tumor eradication by genetically engineering T cells to specifically target HCC-associated antigens, such as Glypican-3 (GPC3), alpha-fetoprotein (AFP), and phosphatidylinositol proteoglycan-3. The gene discussed is GPC3; the disease is neoplasm.